Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.

[1]  F. Gode,et al.  Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. , 2014, Reproductive biomedicine online.

[2]  M. van Wely,et al.  Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. , 2014, The Cochrane database of systematic reviews.

[3]  P. Humaidan,et al.  GnRHa trigger for final oocyte maturation: is HCG trigger history? , 2014, Reproductive biomedicine online.

[4]  K. V. Andersen,et al.  Improving the luteal phase after ovarian stimulation: reviewing new options , 2014 .

[5]  P. Devroey,et al.  Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.

[6]  E. Barzilay,et al.  GnRH Agonist vs. hCG for Triggering of Ovulation – Differential Effects on Gene Expression in Human Granulosa Cells , 2013, PloS one.

[7]  H. Fatemi,et al.  Implantation in assisted reproduction: a look at endometrial receptivity. , 2013, Reproductive biomedicine online.

[8]  E. Papanikolaou,et al.  Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. , 2013, Fertility and sterility.

[9]  B. Ata,et al.  Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. , 2013, Human reproduction.

[10]  N. Fukunaga,et al.  Failure of GnRH agonist-triggered oocyte maturation: its cause and management , 2013, Journal of Assisted Reproduction and Genetics.

[11]  P. Humaidan,et al.  GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.

[12]  Matheus Roque,et al.  Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. , 2013, Fertility and sterility.

[13]  R. Feinn,et al.  Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. , 2013, Human reproduction.

[14]  J. García-Velasco.  Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos. , 2012, Fertility and sterility.

[15]  P. Devroey,et al.  An OHSS-Free Clinic by segmentation of IVF treatment. , 2011, Human reproduction.

[16]  E. Papanikolaou,et al.  GnRH agonist for triggering of final oocyte maturation: time for a change of practice? , 2011, Human reproduction update.

[17]  S. Daneshmand,et al.  Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. , 2011, Fertility and sterility.

[18]  A. Pellicer,et al.  Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome. , 2011, Fertility and sterility.

[19]  J. Forman,et al.  Perinatal outcome of singleton siblings born after assisted reproductive technology and spontaneous conception: Danish national sibling-cohort study. , 2011, Fertility and sterility.

[20]  B. Fisch,et al.  High serum oestradiol concentrations in IVF cycles increase the risk of pregnancy complications related to abnormal placentation. , 2010, Reproductive biomedicine online.

[21]  C. Simón,et al.  Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. , 2008, Human reproduction update.

[22]  J. Nulsen,et al.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.

[23]  E. Kolibianakis,et al.  Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. , 2006, Human reproduction update.

[24]  C. Dirksen,et al.  Single versus double embryo transfer: cost-effectiveness analysis alongside a randomized clinical trial. , 2006, Human reproduction.

[25]  C. Nappi,et al.  A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  Serge Rozenberg,et al.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. , 2002, Human reproduction update.

[27]  Z. Shoham,et al.  Human chorionic gonadotropin: pharmacokinetics of subcutaneous administration. , 1996, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[28]  B. Charbonnel,et al.  Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration. , 1991, Fertility and sterility.

[29]  Z. Rosenwaks,et al.  Beta-human chorionic gonadotropin as a monitor of pregnancy outcome in in vitro fertilization-embryo transfer patients. , 1988, Fertility and sterility.

[30]  A. Zeleznik,et al.  The corpus luteum of the primate menstrual cycle is capable of recovering from a transient withdrawal of pituitary gonadotropin support. , 1985, Endocrinology.

[31]  A. Zeleznik,et al.  The Rhesus Monkey Corpus Luteum Is Dependent on Pituitary Gonadotropin Secretion throughout the Luteal Phase of the Menstrual Cycle , 1984 .